Neurogen
Executive Summary
Harry Penner to president, CEO and a board member of the Branford, Conn. CNS biopharmaceutical R&D firm. Penner, 48, succeeds Philip Whitcome, who is stepping down for personal reasons, Neurogen says Oct. 28. Penner joins the company Dec. 1. Penner, who was at Novo Nordisk 12 years, most recently held the position of company president in the U.S. and a member of the corporate management team. On an interim basis, the New York corporate office will report to Chief Financial Officer Kurt Anker Neilsen.